Open Access

The expression of vasohibin‑1 and its prognostic significance in bladder cancer

  • Authors:
    • Bo Zhang
    • Zhouliang Wu
    • Wanqin Xie
    • Dawei Tian
    • Feiran Chen
    • Chuan Qin
    • Zhiyong Du
    • Gang Tang
    • Qiongqiong Gao
    • Xiaoyu Qiu
    • Changli Wu
    • Jing Tian
    • Hailong Hu
  • View Affiliations

  • Published online on: August 18, 2017     https://doi.org/10.3892/etm.2017.4969
  • Pages: 3477-3484
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Angiogenesis is important in the development of solid tumors. Vasohibin‑1 (VASH‑1) is an endothelium‑derived protein that acts as an inhibitor of angiogenesis in many different types of cancer. However, the expression of VASH‑1 and its clinical value in bladder cancer remain unknown. The current study analyzed the expression of VASH‑1, as well as the expression of the angiogenesis‑related factors vascular endothelial growth factor‑A, hypoxia inducible factor‑1α and cluster of differentiation 34 in bladder cancer tissues from 50 patients using immunohistochemistry. The associations between the expression of these factors and the clinicopathological characteristics of the patients were assessed. The current study demonstrated that VASH‑1 is primarily expressed in the cytoplasm of bladder cancer cells and in a fraction of vascular endothelial cells. Furthermore, the expression of VASH‑1 was positively associated with the tumor stage (P<0.01), pathological grade (P<0.01) and distant metastasis (P<0.05) but not with patient age or sex (P>0.05). Spearman rank correlation tests indicated that levels of those four factors were positively correlated with each other. Kaplan‑Meier analysis indicated that high expression of these four factors was significantly associated with lower 5‑year overall survival and progression‑free survival rates. Collectively, the results of the current study suggest that VASH‑1 is clinically significant in bladder cancer and its high expression may predict the progression and prognosis of patients with bladder cancer. The present study also implies that VASH‑1 may be a novel target for vascular targeting therapy.

Related Articles

Journal Cover

October-2017
Volume 14 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang B, Wu Z, Xie W, Tian D, Chen F, Qin C, Du Z, Tang G, Gao Q, Qiu X, Qiu X, et al: The expression of vasohibin‑1 and its prognostic significance in bladder cancer. Exp Ther Med 14: 3477-3484, 2017
APA
Zhang, B., Wu, Z., Xie, W., Tian, D., Chen, F., Qin, C. ... Hu, H. (2017). The expression of vasohibin‑1 and its prognostic significance in bladder cancer. Experimental and Therapeutic Medicine, 14, 3477-3484. https://doi.org/10.3892/etm.2017.4969
MLA
Zhang, B., Wu, Z., Xie, W., Tian, D., Chen, F., Qin, C., Du, Z., Tang, G., Gao, Q., Qiu, X., Wu, C., Tian, J., Hu, H."The expression of vasohibin‑1 and its prognostic significance in bladder cancer". Experimental and Therapeutic Medicine 14.4 (2017): 3477-3484.
Chicago
Zhang, B., Wu, Z., Xie, W., Tian, D., Chen, F., Qin, C., Du, Z., Tang, G., Gao, Q., Qiu, X., Wu, C., Tian, J., Hu, H."The expression of vasohibin‑1 and its prognostic significance in bladder cancer". Experimental and Therapeutic Medicine 14, no. 4 (2017): 3477-3484. https://doi.org/10.3892/etm.2017.4969